{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:38Z","timestamp":1787962298914,"version":"build-2784847793"},"reference-count":40,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>We aimed to determine the prevalence and incidence, and to identify the factors associated with liver abnormalities in patients with psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>From a longitudinal cohort study, we identified PsA patients with either elevated serum transaminase or alkaline phosphatase levels or liver disease after the first visit to the PsA clinic (cases). Controls were subjects from the same cohort who never had such abnormalities or liver disease. Cases and controls were matched 1:1 by sex, age at the first clinic visit, and followup duration; variables at the onset of the first appearance of liver test abnormality associated with liver abnormalities were identified using univariate logistic and multivariate logistic regression analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Among 1061 patients followed in the PsA clinic, 343 had liver abnormalities. Two hundred fifty-six patients who developed liver abnormalities after the first visit were identified as cases, and 718 patients were identified as controls. The prevalence of liver abnormalities was 32% and the incidence was 39\/1000 patient-years where there were 256 cases over 6533 total person-years in the PsA cohort. Liver abnormalities were detected after a mean (SD) followup duration of 8.3 \u00b1 7.8 years. The common causes of liver abnormalities were drug-induced hepatitis and fatty liver. Independent factors associated with liver abnormalities were higher body mass index (BMI), daily alcohol intake, higher damaged joint count, elevated C-reactive protein, and use of methotrexate, leflunomide, or tumor necrosis factor inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Liver abnormalities are common among patients with PsA and are associated with higher BMI, more severe disease, and certain therapies.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.181312","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T20:13:26Z","timestamp":1571170406000},"page":"847-853","source":"Crossref","is-referenced-by-count":23,"title":["Liver Abnormalities in Patients with Psoriatic Arthritis"],"prefix":"10.3899","volume":"47","author":[{"given":"Rattapol","family":"Pakchotanon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2020060113043300000_47.6.847.1","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/jdv.13674","article-title":"Liver test abnormalities in patients admitted for severe psoriasis: prevalence and associated risk factors","volume":"30","author":"Finet","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020060113043300000_47.6.847.2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/ajd.12460","article-title":"Psoriasis and the liver: problems, causes and course","volume":"58","author":"Tula","year":"2017","journal-title":"Australas J Dermatol"},{"key":"2020060113043300000_47.6.847.3","doi-asserted-by":"crossref","first-page":"3140983","DOI":"10.1155\/2018\/3140983","article-title":"Liver illness and psoriatic patients","volume":"2018","author":"Fiore","year":"2018","journal-title":"Biomed Res Int"},{"key":"2020060113043300000_47.6.847.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.06.008"},{"key":"2020060113043300000_47.6.847.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.020"},{"key":"2020060113043300000_47.6.847.6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/jdv.12847","article-title":"Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis","volume":"29","author":"Candia","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020060113043300000_47.6.847.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2012.00905.x"},{"key":"2020060113043300000_47.6.847.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101378"},{"key":"2020060113043300000_47.6.847.9","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200626020-00001"},{"key":"2020060113043300000_47.6.847.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116194"},{"key":"2020060113043300000_47.6.847.11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4254\/wjh.v10.i2.329","article-title":"Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents","volume":"10","author":"Damiani","year":"2018","journal-title":"World J Hepatol"},{"key":"2020060113043300000_47.6.847.12","first-page":"127","article-title":"Psoriatic arthritis (PSA)--an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"2020060113043300000_47.6.847.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2020060113043300000_47.6.847.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.23104"},{"key":"2020060113043300000_47.6.847.15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322"},{"key":"2020060113043300000_47.6.847.16","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1989.01670140087017"},{"key":"2020060113043300000_47.6.847.17","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"J Invest Derm"},{"key":"2020060113043300000_47.6.847.18","doi-asserted-by":"crossref","first-page":"e4435","DOI":"10.1371\/journal.pone.0004435","article-title":"Epidemiology and genetic epidemiology of the liver function test proteins","volume":"4","author":"Rahmioglu","year":"2009","journal-title":"PLoS One"},{"key":"2020060113043300000_47.6.847.19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2016.178","article-title":"Metabolically healthy obesity and the development of nonalcoholic fatty liver disease","volume":"111","author":"Chang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2020060113043300000_47.6.847.20","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/acr.22294","article-title":"Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record","volume":"66","author":"Schmajuk","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"Suppl 2","key":"2020060113043300000_47.6.847.21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","article-title":"Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity","volume":"25","author":"Montaudie","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020060113043300000_47.6.847.22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/1996\/213596","article-title":"Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up","volume":"10","author":"Malatjalian","year":"1996","journal-title":"Can J Gastroenterol"},{"key":"2020060113043300000_47.6.847.23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/annrheumdis-2016-210629","article-title":"Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate","volume":"76","author":"Humphreys","year":"2017","journal-title":"Ann Rheum Dis Online"},{"key":"2020060113043300000_47.6.847.24","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jhep.2010.04.043","article-title":"Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study","volume":"53","author":"Laharie","year":"2010","journal-title":"J Hepatol"},{"key":"2020060113043300000_47.6.847.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111391"},{"key":"2020060113043300000_47.6.847.26","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin","year":"1998","journal-title":"J Rheumatol"},{"key":"2020060113043300000_47.6.847.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.10935"},{"key":"2020060113043300000_47.6.847.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.11331"},{"key":"2020060113043300000_47.6.847.29","doi-asserted-by":"publisher","DOI":"10.1080\/08977190500095980"},{"key":"2020060113043300000_47.6.847.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01826.x"},{"key":"2020060113043300000_47.6.847.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172666"},{"key":"2020060113043300000_47.6.847.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0678-9"},{"key":"2020060113043300000_47.6.847.33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep023"},{"key":"2020060113043300000_47.6.847.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.20253"},{"key":"2020060113043300000_47.6.847.35","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12045"},{"key":"2020060113043300000_47.6.847.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2020060113043300000_47.6.847.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204902"},{"key":"2020060113043300000_47.6.847.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2020060113043300000_47.6.847.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202245"},{"key":"2020060113043300000_47.6.847.40","doi-asserted-by":"crossref","first-page":"561748","DOI":"10.1155\/2013\/561748","article-title":"Autoimmune hepatitis triggered by anti-TNF-alpha therapy","volume":"2013","author":"Nakayama","year":"2013","journal-title":"Case Rep Med"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.181312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T20:05:26Z","timestamp":1591041926000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.181312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,1]]},"published-print":{"date-parts":[[2020,6,1]]}},"alternative-id":["10.3899\/jrheum.181312"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.181312","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]}}}